Jennifer R. Cochran - Net Worth and Insider Trading

Jennifer R. Cochran Net Worth

The estimated net worth of Jennifer R. Cochran is at least $347,092 dollars as of 2024-04-28. Jennifer R. Cochran is the Director of OmniAb Inc and owns about 77,476 shares of OmniAb Inc (OABI) stock worth over $347,092. Details can be seen in Jennifer R. Cochran's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jennifer R. Cochran has not made any transactions after 2022-12-06 and currently still holds the listed stock(s).

Transaction Summary of Jennifer R. Cochran

Jennifer R. Cochran Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jennifer R. Cochran owns 3 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Avista Public Acquisition Corp II (AHPA) , and OmniAb Inc (OABI) .

Click here to see the complete history of Jennifer R. Cochran’s form 4 insider trades.

Insider Ownership Summary of Jennifer R. Cochran

Ticker	Comapny	Transaction Date	Type of Owner
LGND	Ligand Pharmaceuticals Inc	2021-07-12	director
AHPA	Avista Public Acquisition Corp II	2022-11-01	director
OABI	OmniAb Inc	2022-12-06	director

Jennifer R. Cochran Latest Holdings Summary

Jennifer R. Cochran currently owns a total of 1 stock. Jennifer R. Cochran owns 77,476 shares of OmniAb Inc (OABI) as of December 6, 2022, with a value of $347,092.

Latest Holdings of Jennifer R. Cochran

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
OABI	OmniAb Inc	2022-12-06	77,476	4.48	347,092

Holding Weightings of Jennifer R. Cochran

Jennifer R. Cochran Form 4 Trading Tracker

According to the SEC Form 4 filings, Jennifer R. Cochran has made a total of 2 transactions in OmniAb Inc (OABI) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in OmniAb Inc is the acquisition of 22,250 shares on December 6, 2022, which cost Jennifer R. Cochran around $83,438.

Insider Trading History of Jennifer R. Cochran

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jennifer R. Cochran Trading Performance

GuruFocus tracks the stock performance after each of Jennifer R. Cochran's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jennifer R. Cochran is 31.36%. GuruFocus also compares Jennifer R. Cochran's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jennifer R. Cochran within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jennifer R. Cochran's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jennifer R. Cochran

Average Return

34.2%

Average return per transaction

Outperforming Transactions

100%

2 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	3.61	31.36	14.2	34.2
Relative Return to S&P 500(%)	4.93	28.92	8.13	21.2

Jennifer R. Cochran Ownership Network

Ownership Network List of Jennifer R. Cochran

No Data

Ownership Network Relation of Jennifer R. Cochran

Jennifer R. Cochran Owned Company Details

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

Jennifer R. Cochran is the director of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include Chief Financial Officer Octavio Espinoza , CHIEF LEGAL OFFICER & Andrew Reardon , and CEO & President John L Higgins .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, Jennifer R. Cochran made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 20,000 shares made by John L Higgins , a net sale of 10,852 shares made by John W Kozarich , and a net sale of 8,301 shares made by Stephen L Sabba .

In summary, during the past 3 months, insiders sold 2,033 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 2,033 shares. During the past 18 months, 41,289 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 37,289 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

What does Avista Public Acquisition Corp II do?

Who are the key executives at Avista Public Acquisition Corp II?

Jennifer R. Cochran is the director of Avista Public Acquisition Corp II. Other key executives at Avista Public Acquisition Corp II include director & 10 percent owner David F Burgstahler , director & 10 percent owner Thompson Dean , and director & 10 percent owner Avista Acquisition Gp Llc Ii .

Avista Public Acquisition Corp II (AHPA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Avista Public Acquisition Corp II (AHPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Avista Public Acquisition Corp II (AHPA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Avista Public Acquisition Corp II (AHPA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avista Public Acquisition Corp II Insider Transactions

No Available Data

What does OmniAb Inc do?

Who are the key executives at OmniAb Inc?

Jennifer R. Cochran is the director of OmniAb Inc. Other key executives at OmniAb Inc include EVP & Finance and CFO Kurt A Gustafson , See Remarks Charles S Berkman , and director & President & CEO Matthew W Foehr .

OmniAb Inc (OABI) Insider Trades Summary

Over the past 18 months, Jennifer R. Cochran made 2 insider transaction in OmniAb Inc (OABI) with a net purchase of 52,250. Other recent insider transactions involving OmniAb Inc (OABI) include a net purchase of 1,670,000 shares made by Matthew W Foehr , a net sale of 60,000 shares made by John L Higgins , and a net sale of 8,803 shares made by Kurt A Gustafson .

In summary, during the past 3 months, insiders sold 25,757 shares of OmniAb Inc (OABI) in total and bought 225,000 shares, with a net purchase of 199,243 shares. During the past 18 months, 85,757 shares of OmniAb Inc (OABI) were sold and 1,811,250 shares were bought by its insiders, resulting in a net purchase of 1,725,493 shares.

OmniAb Inc (OABI)'s detailed insider trading history can be found in Insider Trading Tracker table.

OmniAb Inc Insider Transactions

No Available Data

Jennifer R. Cochran Mailing Address

Above is the net worth, insider trading, and ownership report for Jennifer R. Cochran. You might contact Jennifer R. Cochran via mailing address: C/o Ligand Pharmaceuticals Inc, 3911 Sorrento Valley Boulevard, Ste 100, San Diego Ca 92121.

Discussions on Jennifer R. Cochran

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.